Risk-adapted Therapy in Low-risk HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Status:
Recruiting
Trial end date:
2032-06-01
Target enrollment:
Participant gender:
Summary
This research is being conducted to understand if treatment can be tailored for participants
with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking
status) combined with an investigational HPV blood test.
The names of the test and treatments involved in this study are:
- NavDx® HPV ctDNA testing (HPV blood test)
- Radiation therapy
- Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any
or all of these agents)